Perspective Therapeutics (CATX) Shares Outstanding (Diluted Average) (2023 - 2026)

Perspective Therapeutics has disclosed Shares Outstanding (Diluted Average) across 4 years of filings, most recently posting $103.6 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $103.6 million, up 43.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $103.6 million (up 43.18% YoY), and the FY2025 annual result was $73.8 million, up 14.57% from the prior year.
• Shares Outstanding (Diluted Average) came in at $103.6 million for Q1 2026 at Perspective Therapeutics, up from $73.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $228.6 million in Q1 2023 to a low of $26.8 million in Q4 2023.
• The 4-year median for Shares Outstanding (Diluted Average) is $70.6 million (2024), against an average of $73.2 million.
• Peak annual rise in Shares Outstanding (Diluted Average) reached 151.75% in 2024, while the deepest fall reached 78.34% in 2024.
• Perspective Therapeutics' Shares Outstanding (Diluted Average) stood at $26.8 million in 2023, then jumped by 140.72% to $64.4 million in 2024, then climbed by 14.57% to $73.8 million in 2025, then surged by 40.36% to $103.6 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $103.6 million (Q1 2026), $73.8 million (Q4 2025), and $74.3 million (Q3 2025), per Business Quant data.